Pharmaceutical Executive May 13, 2022
Dharmendra Sahay, Vijesh Unnikrishnan

Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.

For over a decade, the pharmaceutical and biotech industry has invested steadily in digital and connected health capabilities aimed at improving outcomes with patient-centric solutions.1 But progress has been slow, and confidence in the impact of digital health initiatives has dwindled. In a recent ZS survey, fewer than half of pharma executives reported generating value from their investments in digital initiatives broadly, including patient digital efforts.

While pharma contemplates its role in the future of digital health, other players are doubling down. New digitally native entrants are reframing the definition of outcomes more holistically in behavioral, functional, and clinical spheres that span therapy areas...

Today's Sponsors

Canton & Company
Curation Health

Today's Sponsors

Oliver Wyman

Today's Sponsor

Canton & Company

Topics: Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology
Study: Many digital health startups lack clinical trials, regulatory filings
Closing the digital expectation gap in pharma
Pfizer: Pharma needs a business strategy for a digital world
Survey: Pharma bullish on digital innovation, but failing on execution
Clinical Trial Focuses on Remote Monitoring of Cancer Patients